ArticleACS medicinal chemistry letters2024

Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis.

Ram W SabnisPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.